Results 81 to 90 of about 13,243,531 (353)

Determinants of Cross-Sectional Variation in Discount Rates, Growth Rates, and Exit Cap Rates [PDF]

open access: yes
This study investigates the determinants of key input variables in valuers’ DCF models used for estimating market values for offices. Data from 599 valuations in 2000 from Stockholm, Gothenburg and Malmö are used to explain variation in discount rates ...
Bo SÖDERBERG   +3 more
core  

A PRSZT Registry Analysis of Prognostic Factors Influencing Survival and Relapse Rates After Second Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoblastic Leukemia

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT A second allogeneic (allo‐)hematopoietic stem cell transplantation (HSCT2) is a potential curative option for pediatric patients with acute lymphoblastic leukemia (ALL) following relapse after first allogeneic transplantation (HSCT1), but its efficacy is limited by high relapse rates and transplant‐related toxicity in highly pretreated ...
Ava Momm   +10 more
wiley   +1 more source

Motivational Ratings

open access: yesThe Review of Economic Studies, 2016
AbstractPerformance evaluation (“rating”) systems not only provide information to users but also motivate the rated worker. This article solves for the optimal (effort-maximizing) rating within the standard career concerns framework. We prove that this rating is a linear function of past observations.
Hörner, Johannes, Lambert, Nicolas
openaire   +3 more sources

Gemcitabine, Docetaxel, Melphalan, Carboplatin as Part of Sequential Cycles of High‐Dose Chemotherapy With Autologous Hematopoietic Stem‐Cell Rescue for Multiply Relapsed/Refractory Pediatric Germ Cell Tumors

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Although most malignant germ cell tumors (GCTs) are highly curable with cisplatin‐based therapy, options for patients with multiply relapsed/refractory disease remain limited. For this population, we report the first pediatric use of gemcitabine, docetaxel, melphalan, and carboplatin (GemDMC) as part of sequential cycles of high‐dose ...
Maria Frost   +10 more
wiley   +1 more source

The Tempo and Quantum of Life Cycle Events [PDF]

open access: yesVienna Yearbook of Population Research, 2006
This study develops and applies a general framework for the analysis of the period quantum and tempo of life-cycle events, extending methods developed previously by the authors.
Griffith Feeney, John Bongaarts
doaj  

Credible ratings [PDF]

open access: yesTheoretical Economics, 2006
published_or_final_version
Damiano, Ettore, Li, Hao, Suen, Wing
openaire   +4 more sources

CPX‐351 in High‐Risk Relapsed Pediatric Acute Leukemia: Real‐World Phase 1 Data Establishing the FDA‐Approved Dose

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background/Objectives Outcomes for pediatric relapsed/refractory (R/R) acute myeloid leukemia (AML) remain dismal. CPX‐351, a liposomal formulation of cytarabine and daunorubicin, may have less off‐target toxicities than traditional chemotherapies and has shown improved outcomes for adults with newly diagnosed therapy‐related AML.
Jonathan D. Bender   +17 more
wiley   +1 more source

INSTITUTIONAL EXTERNALITIES AS FACTORS OF INSTITUTIONAL CHANGES

open access: yesВестник Кемеровского государственного университета, 2013
The article states the authors' hypothesis about the ability of institutes and institutional formations to produce the external, side effects (externalities) which transforms them in one of the factors of the institutional changes.
T. A. Mikhailova
doaj  

Novel Genetic Risk Factor Identified for L‐Asparaginase‐Induced Pancreatitis in Pediatric Patients With Cancer

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background L‐asparaginase is a critical component in treatment protocols for pediatric acute lymphoblastic leukemia. Acute pancreatitis reactions can necessitate delays and, in some cases, discontinuation of L‐asparaginase, which compromises outcomes.
Edward J. Raack   +39 more
wiley   +1 more source

Home - About - Disclaimer - Privacy